Join the Rybelsus group to help and get support from people like you.
Rybelsus News (Page 2)
Studies Address Muscle Loss Caused By GLP-1 Drugs, such as Ozempic and Zepbound
TUESDAY, June 24, 2025 — GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with fat. Experts are now turning their attention t...
Semaglutide Offers Cardiovascular Edge Over Empagliflozin in Type 2 Diabetes
FRIDAY, June 20, 2025 – For patients aged 45 years or older with type 2 diabetes, semaglutide seems to confer some advantage over empagliflozin in terms of mortality and cardiovascular event risks,...
Few Adolescents With Obesity Prescribed Obesity Medications
FRIDAY, June 13, 2025 – Despite an increase in the prevalence of prescribing, only 0.5 percent of U.S. adolescents with obesity were prescribed an obesity medication in 2023, according to research...
Real-World Weight Loss With Semaglutide, Tirzepatide Less Than That Seen in Clinical Trials
THURSDAY, June 12, 2025 – For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent on average, which is lower than the percentages...
Real-World Results For GLP-1 Drugs Underwhelm, Study Says
WEDNESDAY, June 11, 2025 — Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren’t as impressive as those promised by the drugs’ clinical trials, a new study says....
American Society of Clinical Oncology, May 31-June 3
The annual meeting of the American Society of Clinical Oncology was held from May 31 to June 3 in Chicago and hosted more than 35,000 participants, including clinicians, academicians, allied health p...
ASCO: GLP-1 Receptor Agonists May Reduce Risk for Obesity-Related Cancer, All-Cause Death
WEDNESDAY, May 28, 2025 – For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for obesity-related cancer compared with...
Weight-Loss Drugs May Lower Risk Of Obesity-Related Cancers
WEDNESDAY, May 28, 2025 — Popular GLP-1 weight loss drugs like Ozempic and Zepbound can help reduce a woman’s risk for as many as 14 cancers associated with obesity, a new study says. People taking a ...
Semaglutide Plus Intensive Behavioral Therapy Most Beneficial for Weight Loss
FRIDAY, May 23, 2025 – Weight loss treatment combining personalized semaglutide with intensive behavioral therapy (IBT) yields weight loss similar to that reported in confirmatory trials, with a...
FDA Halts Sale of Off-Brand Ozempic and Other GLP-1 Drugs
FRIDAY, May 23, 2025 — A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on. The U.S. Food and Drug A...
GLP-1 Receptor Agonists Not Linked to Increased Risk of Psychiatric Adverse Events, Depression
MONDAY, May 19, 2025 – For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased risk for psychiatric...
GLP-1 Weight Loss Drugs Cut Alcohol Cravings By Two-Thirds
TUESDAY, May 13, 2025 — Cutting-edge weight-loss drugs like Ozempic/Wegovy can cut alcohol intake dramatically in a short amount of time, a new study says. People taking semaglutide or liraglutide r...
GLP-1 Receptor Agonists Reduce Alcohol Intake in Patients Treated for Obesity
MONDAY, May 12, 2025 – Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are tied to a reduction in alcohol intake, according to a research letter recently published in Diabetes, Obesity and...
Semaglutide Beneficial in Metabolic Dysfunction-Associated Steatohepatitis, Fibrosis
FRIDAY, May 2, 2025 – For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes, according to a study...
Adverse Events From Semaglutide Seen in the ED Usually GI-Related
TUESDAY, April 15, 2025 – The rate of emergency department visits for adverse events among patients dispensed semaglutide is low, with most visits involving gastrointestinal effects, according to a...